Thyroid cancer

Differentiated Thyroid Cancer
- Advanced radioactive iodine refractory
  - IRB #15341
    - A Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose
- No Studies Available

Medullary Thyroid Cancer
- No Studies Available

Anaplastic Thyroid Cancer
- IRB #15572
  - An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

7/23/2017